Seeking Alpha
28 May 2026, 19:32 UTC · 16w ago
Verdict
Headline takes no side. We score IONS +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 94% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Ionis Pharmaceuticals projects 2030 revenues to exceed $5 billion.
So whatSubstantial long-term revenue growth targets typically drive significant valuation increases in biotech.
More positive than 99% of claims this week
The company is transitioning from niche indications to multi-billion-dollar markets via product launches and partnerships.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 92% of claims this week
Revenue growth will be driven by Tryngolza, Dawnzera, and royalties from eplontersen, bepiroversen, and pelacarsen.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
The company is rated as a Buy with strong revenue projections and a transition into multi-billion-dollar markets.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−40.2%
Price is moving against the score
$45.75 vs $76.49 close before publication (May 27) · not market-adjusted
IONS chart →
